WordPress database error: [Error writing file '/tmp/MYNWpq5E' (Errcode: 28 - No space left on device)]
SELECT post_id, meta_key, meta_value FROM wp_postmeta WHERE post_id IN (14308,14309,14342) ORDER BY meta_id ASC

Clinical Trial Finder – Sickle Cell Studies
SICKLE CELL STUDIES

Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Featured Study

THRIVE-132: Therapy for Reduction in VOC Readmissions with Inclacumab
An Electronic Patient Reported Pain Assessment in Sickle Cell
Hibiscus Study: An oral investigational medication for SCD
THRIVE-131: A study to potentially reduce VOCs in sickle cell
Filters
Sort by
Apply Filters Clear Filters
Filters
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)

This is a multicenter, prospective, single-arm observational non-interventional study (NIS), which will be conducted in various countries in the Middle East and India.

Age

Years

LEARN MORE
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD).

Age

Years

LEARN MORE
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD).

Age

Years

LEARN MORE